Workshop ”InDeCS-H: Development of Healthcare Biotechnology SMEs“
This presentation is the property of its rightful owner.
Sponsored Links
1 / 12

Workshop ”InDeCS-H: Development of Healthcare Biotechnology SMEs“ 10 th September 2009 Budapest PowerPoint PPT Presentation


  • 93 Views
  • Uploaded on
  • Presentation posted in: General

Workshop ”InDeCS-H: Development of Healthcare Biotechnology SMEs“ 10 th September 2009 Budapest Strategy for Hungarian pharmaceutical and biotechnology industry András BAKÁCS Head of Department Department for Knowledge Economy Ministry for National Development and Economy. Background.

Download Presentation

Workshop ”InDeCS-H: Development of Healthcare Biotechnology SMEs“ 10 th September 2009 Budapest

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Workshop indecs h development of healthcare biotechnology smes 10 th september 2009 budapest

Workshop ”InDeCS-H: Development of Healthcare Biotechnology SMEs“

10th September 2009

Budapest

Strategy for Hungarian pharmaceutical and biotechnology industry

András BAKÁCS

Head of Department

Department for Knowledge Economy

Ministry for National Development and Economy


Background

Background

  • August 2008: new concept in the Hungarian development policy: sector specific industrial and innovation policy programmes shall be prepared

  • October 2008: the financial and economic crisis further emphasized the need for sector specific development policy


Priority sectors

Priority sectors

  • Priority sectors chosen by the Government:

    • ICT,

    • pharmaceutical industry and biotechnology,

    • automotive industry,

    • logistics,

  • Why these sectors?

    • knowledge-intensive

    • high growth and value added capacity

    • contribution to the competitiveness of the economy


Strategy and action plan

Strategy and Action Plan

  • The Pharmaceutical and Biotechnology Action Plan was adopted by the Government on 8th July 2009

  • The Action Plan is based on the main findings of two preparatory studies prepared by KPMG and HBA

  • The Action Plan focuses on healthcare biotech


Relation between pharmaceuticals and biotechnology

Relation between pharmaceuticals and biotechnology

Hungarian red biotech sector

Hungarian Pharma Industry

Mostly private SMEs, less than 25-50 employees

Young sector: All companies established after 1990, most of them after 2000

Hungarian ownership

Rapid growth, acquisitions

High risk, slow return original R&D activity

Most of the turnover comes from global markets, B2B relation, from services

Major problems are related to R&D, enterprise development, accessing international markets

Some large companies, registered on the stock exchange

Traditional: Companies established before 1990, some of them before world war I

Multinational owners

Organic growth

Low risk, generic R&D activity

Most of the turnover comes from domestic and neighbouring markets, B2C relation, from products

Major problems are related to consumption and sale, costs and profits in relation to pricing and reimbursement system

Source: Convincive Consulting, 2008


Pharmaceutical industry in hungary

Pharmaceutical industry in Hungary

  • 100 years expertise

  • 75% of turnover from exports, 15 000 employees

  • 53% of the complete turnover produced by the 10 largest companies


Goals

Goals

  • General objectives:

    • To provide favourable regulatory and development policy environment in order to increase the competitiveness of pharma and biotech companies in Hungary

  • Specific objectives of the Action Plan:

    • To promote the restructuring of Hungarian pharma industry according to international trends, building on the advantages of domestic biotech sector

    • To enhance the role of biotechnology in pharmaceutical innovation and to increase the number of international R&D centers based on domestic knowledge

    • To promote university industrial relations, mobility, human resources, knowledge transfer

    • To enhance the role of biotech sector in accessing markets for domestic pharmaceutical research


Pillar i r d

Pillar I: R&D

  • Taking into account the specific features of pharma and biotech industry in resource allocation

  • Enhancing the increase of R&D expenditures by tax regulation

  • Promoting access to finance of biotech SMEs

  • Introducing Young Innovative Company (YIC) status in Hungary

  • Streamlining the incubator programmes

  • Promotion of life sciences and scientific studies to young people

  • Providing the necessary human resource supply for pharma and biotech R&D by education and attracting experts working abroad

  • Better exploitation of clinical R&D


Pillar ii p roduction

Pillar II:Production

  • Promoting pharma and biotech investments in Hungary by active marketing and investment promotion programs

  • Providing the necessary human resource supply for pharma and biotech R&D by education and attracting experts and sector managers working abroad


Pillar iii regulatory environment

Pillar III: Regulatory environment

  • Reconsidering of the sector-specific regulatory environment, analysis of tax and legal burdens on pharma industry and biotech companies from the competitiveness point of view and harmonise them with the practice of neighbouring countries

  • Accelerating the drug registration process


Conclusions

Conclusions

The first year of governmental industrial policy has significant results:

  • The government and the industry have started an active cooperation,

  • A R&D related tax allowance will be introduced next year: 20% in 2010 and 100% in 2011


Workshop indecs h development of healthcare biotechnology smes 10 th september 2009 budapest

Thank you for your kind attention!

[email protected]


  • Login